There is a good article on Bloomberg Health Care page today that discusses Glaxo's search for new drugs outside its own labs and how this is being made more difficult by increased competition by rivals desparate for novel treatments.
The article also discusses the increased thirst of big pharma because their own labs aren't developing drugs to replace those coming off patent and which are being replaced by lower-priced copies.
The CEO of Glaxo notes they lose deals because some competitors pay too rich a price for some drugs.
I thought the article was informative as to the mindset and problems facing big pharma as they discuss partnering with OGXI.
I saw that article a few days ago. It does underscore that small biotechs with quality products underpineed with strong clinical results are in a sweet spot.
OGX-011 thus far has demonstrated very robust surival results with statistical signficance....its safety profile is very attractive....and the potential profit margins are very promising considering the low cost to manufacture.
Couple that with a large indication (CRPC) that is very much in need of new drugs to extend survial....along with OgX-011 application to other indicatiions (e.g. NSCLC)...also other pipeline candidates that have a targeted mechanism (OgX-427)....and a very undervalued stock price based on a number of valuation methodologies.......considering all these things gives one a sense that this is one biotech you want to hold and allow the embedded value to be realized.
When one is dealing with quality data in so many respects...you grab a piece of the action before the rest of the market catches up.